Abstract: Ivermectin is a US Food and Drug Administration (FDA)-approved antiparasitic agent with antiviral and anti-inflammatory properties. Although recent studies reported the possible anti-inflammatory activity of ivermectin in respiratory injuries, its potential therapeutic effect on pulmonary fibrosis (PF) has not been investigated. This study aimed to explore the ability of ivermectin (0.6 mg/kg) to alleviate bleomycin-induced biochemical derangements and histological changes in an experimental PF rat model. This can provide the means to validate the clinical utility of ivermectin as a treatment option for idiopathic PF. The results showed that ivermectin mitigated the bleomycin-evoked pulmonary injury, as manifested by the reduced infiltration of inflammatory cells, as well as decreased the inflammation and fibrosis scores. Intriguingly, ivermectin decreased collagen fiber deposition and suppressed transforming growth factor-‍β1 (TGF-‍β1) and fibronectin protein expression, highlighting its anti-fibrotic activity. This study revealed for the first time that ivermectin can suppress the nucleotide-binding oligomerization domain (NOD)‍-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome, as manifested by the reduced gene expression of NLRP3 and the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), with a subsequent decline in the interleukin‍-‍1β (IL‍-‍1β) level. In addition, ivermectin inhibited the expression of intracellular nuclear factor-‍κB (NF‍-‍κB) and hypoxia‑inducible factor‑1α (HIF‍-‍1α) proteins along with lowering the oxidative stress and apoptotic markers. Altogether, this study revealed that ivermectin could ameliorate pulmonary inflammation and fibrosis induced by bleomycin. These beneficial effects were mediated, at least partly, via the downregulation of TGF-‍β1 and fibronectin, as well as the suppression of NLRP3 inflammasome through modulating the expression of HIF‑1α and NF-‍κB.

伊维菌素抑制NLRP3炎症小体可改善博来霉素诱导的肺纤维化

[1]AmbardarSR, HightowerSL, HuprikarNA, et al., 2021. Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic. J Clin Med, 10(11):2452.

[2]BlobeGC, SchiemannWP, LodishHF, 2000. Role of transforming growth factor β in human disease. N Engl J Med, 342(18):1350-1358.

[3]BuonfrateD, BisoffiZ, 2021. Standard dose ivermectin for COVID-19. Chest, 159(5):2111-2112.

[4]CalyL, DruceJD, CattonMG, et al., 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, 178:104787.

[5]ChenL, WangT, WangX, et al., 2009. Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats. Respir Res, 10:55.

[6]ChenTT, XiaoF, LiN, et al., 2021. Inflammasome as an effective platform for fibrosis therapy. J Inflamm Res, 14:1575-1590.

[7]CiXX, LiHY, YuQL, et al., 2009. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol, 23(4):449-455.

[8]DingN, WeiB, FuXH, et al., 2020. Natural products that target the NLRP3 inflammasome to treat fibrosis. Front Pharmacol, 11:591393.

[9]GadES, SalamaAAA, El-ShafieMF, et al., 2020. The anti-fibrotic and anti-inflammatory potential of bone marrow-derived mesenchymal stem cells and nintedanib in bleomycin-induced lung fibrosis in rats. Inflammation, 43(1):123-134.

[10]GazdharA, SusuriN, HostettlerK, et al., 2013. HGF expressing stem cells in usual interstitial pneumonia originate from the bone marrow and are antifibrotic. PLoS ONE, 8(6):e65453.

[11]GonçalvesK, VasconcelosA, BarbiratoD, et al., 2020. Therapeutic potential of ivermectin for COVID-19. Authorea, preprint.

[12]HanYY, JiangM, HeRL, et al., 2021. Mefunidone ameliorates bleomycin-induced pulmonary fibrosis in mice. Front Pharmacol, 12:713572.

[13]HuangJJ, XiaJ, HuangLL, et al., 2019. HIF-1α promotes NLRP3 inflammasome activation in bleomycin-induced acute lung injury. Mol Med Rep, 20(4):3424-3432.

[14]JiangQ, GengXK, WarrenJ, et al., 2020. Hypoxia inducible factor-1α (HIF-1α) mediates NLRP3 inflammasome-dependent-pyroptotic and apoptotic cell death following ischemic stroke. Neuroscience, 448:126-139.

[15]KanXC, ChenYS, HuangBX, et al., 2021. Effect of Palrnatine on lipopolysaccharide-induced acute lung injury by inhibiting activation of the Akt/NF-κB pathway. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(11):929-940.

[16]KosynaFK, NagelM, KluxenL, et al., 2015. The importin α/β‍-specific inhibitor ivermectin affects HIF-dependent hypoxia response pathways. Biol Chem, 396(12):‍1357-1367.

[17]KrolewieckiA, LifschitzA, MoragasM, et al., 2021. Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial. eClinicalMedicine, 37:100959.

[18]LatzE, XiaoTS, StutzA, 2013. Activation and regulation of the inflammasomes. Nat Rev Immunol, 13(6):397-411.

[19]LechowiczK, DrożdżalS, MachajF, et al., 2020. COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med, 9(6):1917.

[20]LinX, BarravecchiaM, KottmannRM, et al., 2019. Caveolin-1 gene therapy inhibits inflammasome activation to protect from bleomycin-induced pulmonary fibrosis. Sci Rep, 9:19643.

[21]LiuY, LuFA, KangLR, et al., 2017. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulm Med, 17:63.

[22]MansourSM, ShammaRN, AhmedKA, et al., 2021. Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: a preclinical tolerance study. Int Immunopharmacol, 99:108004.

[23]MittalN, MittalR, 2021. Inhaled route and anti-inflammatory action of ivermectin: do they hold promise in fighting against COVID-19? Med Hypotheses, 146:110364.

[24]RaghuG, BrownKK, CollardHR, et al., 2017. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med, 5(1):22-32.

[25]RodriguesTS, de SáKSG, IshimotoAY, et al., 2021. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med, 218(3):e20201707.

[26]Ruiz-RiolM, BerdnikD, LlanoA, et al., 2017. Identification of interleukin-27 (IL-27)/IL-27 receptor subunit alpha as a critical immune axis for in vivo HIV control. J Virol, 91(16):e00441-17.

[27]SagooP, GarciaZ, BreartB, et al., 2016. In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity. Nat Med, 22(1):64-71.

[28]ShinJW, SeolIC, SonCG, 2010. Interpretation of animal dose and human equivalent dose for drug development. J Korean Orient Med, 31(3):1-7.

[29]SiaDK, MensahKB, Opoku-AgyemangT, et al., 2020. Mechanisms of ivermectin-induced wound healing. BMC Vet Res, 16:397.

[30]SteinhoffM, VocansonM, VoegelJJ, et al., 2016. Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments. Adv Ther, 33:‍1481-1501.

[31]TianR, ZhuY, YaoJY, et al., 2017. NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis. Exp Cell Res, 357(2):328-334.

[32]VriendJ, ReiterRJ, 2016. Melatonin and the von Hippel‒Lindau/HIF-1 oxygen sensing mechanism: a review. Biochim Biophys Acta Rev Cancer, 1865(2):176-183.

[33]WangJP, WangH, FangF, et al., 2021. Danggui Buxue Tang ameliorates bleomycin-induced pulmonary fibrosis by suppressing the TLR4/NLRP3 signaling pathway in rats. Evid Based Complement Alternat Med, 2021:8030143.

[34]WangZY, LiXN, ChenH, et al., 2021. Resveratrol alleviates bleomycin-induced pulmonary fibrosis via suppressing HIF-1α and NF-κB expression. Aging, 13(3):4605-4616.

[35]ZhangX, SongY, CiX, et al., 2008. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflammation Res, 57(11):524-529.